Go to top of page
Incidence of MACE and Percentage of MACE Toxicity in Lung Cancer Patients Receiving ICI
(A) Incidence of MACE in lung cancer patients receiving ICI. (B) Percentage of MACE toxicity severity based on CTCAE grading. (A) Among 196 patients, 23 (11%) patients receiving ICI developed MACE, including NSTEMI (n = 3); myocarditis (n = 9); SVT (n = 7); and pericardial disorders (n = 4). (B) A majority of MACE were grade 3 toxicity (75%), with 3 patients (13%) experiencing grade 5 toxicity (death). CTCAE = common terminology for clinical adverse event; NSTEMI: non-ST-segment elevation myocardial infarction; SVT = supraventricular tachycardia.